In 2008, Eli Lilly and Co. picked up the pieces of Imclone Systems Inc. following a failed hostile takeover bid from Bristol-Myers Squibb Co. Olaratumab (IMC-3G3, LY-3012207) – an early stage asset during that $6.5-billion deal, whose centerpiece was the EGFR inhibitor Erbitux (cetuximab) – on Wednesday gained accelerated approval from the FDA to treat adults with soft tissue sarcoma (STS).